Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism.
Goldstein
J A
JA
Laboratory of Biochemical Risk Analysis, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, USA.
Blaisdell
J
J
D000927:Anticonvulsants / Q000378:metabolism*; D001189:Aryl Hydrocarbon Hydroxylases; D001483:Base Sequence; D065731:Cytochrome P-450 CYP2C19; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics* / Q000378:metabolism*; D017931:DNA Primers / Q000235:genetics; D005821:Genetic Techniques / Q000706:statistics & numerical data; D005838:Genotype; D006801:Humans; D008617:Mephenytoin / Q000378:metabolism*; D006899:Mixed Function Oxygenases / Q000235:genetics* / Q000378:metabolism*; D008969:Molecular Sequence Data; D009154:Mutation; D010641:Phenotype; D016133:Polymerase Chain Reaction / Q000379:methods / Q000706:statistics & numerical data; D011110:Polymorphism, Genetic; D012680:Sensitivity and Specificity
D000927:Anticonvulsants; D017931:DNA Primers; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D008617:Mephenytoin